Silence Therapeutics PLC (LON:SLN) is presenting data to an industry conference on its lead drug that suggests it is a "promising candidate" for the treatment of iron overload and anaemia.
Researchers have been assessing its potential use in Beta-Thalassemia - a blood disorder reduces the production of haemoglobin - and related ailments.
WATCH: Silence Therapeutics 'in a hot space with few competitors'
Silence's drug discovery project leader, Dr Ute Schaeper, will be presenting data on the company's small interfering RNA (siRNA) conjugate technology and lead candidate SLN124.
She will do this at the Annual European Hematology Association Congress on Saturday (June 16) in Stockholm.
Schaeper's team has been able to demonstrate that their GalNAc-conjugated siRNA , which is designed to silence TMPRSS6 in hepatocytes, may provide a "safe, effective and patient-friendly therapeutic option for the treatment of iron overload disorders".
Investors were told: "SLN124 shows dose-dependent and long-lasting effects on target levels as well as on modulation of iron stores and normalisation of erythropoiesis in relevant disease models. We believe that SLN124's mechanism of action and profile will potentially deliver an improved approach to patients in need."